BioPharma Dive 6. Apr. 2026 Under-the-skin Tepezza comparable to infused version in key study, Amgen says
BioPharma Dive 2. Apr. 2026 Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
BioPharma Dive 1. Apr. 2026 Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive 1. Apr. 2026 A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma